Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
Recruiting now
Conditions studied: Lung Cancer, Non-Small Cell, Immunotherapy
In brief
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.
Key facts
- Study ID
- NCT07166003
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- People needed
- 500
- Starts
- 2025-04-20
- Expected to finish
- 2030-04-14
- Last updated by the study team
- 2025-09-10
Who can join
Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aged between 18 and 79 years;
- Received at least two cycles of neoadjuvant immunotherapy;
- ECOG performance status score of 0;
- Complete clinical information including imaging data available.
You may not qualify if…
- Diagnosed with or suspected active autoimmune diseases;
- Presence of EGFR/ALK sensitive mutations;
- Pregnant or breastfeeding women;
- Previous anti-tumor therapies including chemotherapy or radiotherapy;
- History of organ transplantation or hematopoietic stem cell transplantation;
- Interstitial pneumonia, pulmonary fibrosis, or severe emphysema;
- Uncontrolled diabetes mellitus;
- Uncontrolled hypertension.
Where it is running
- Cancer Hospital Chinese Academy of Medical Sciences — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.